| Price | $0.95 |
| Year Range | $0.95 – $9.79 |
| Market Cap | $17M |
| Industry | Biotechnology |
What Is Tempest Therapeutics’s AI Stock Analysis?
Tempest Therapeutics’s AI stock analysis on AltIndex combines the company’s fundamentals, price technicals and 25+ alternative data signals — like hiring, web traffic, app downloads and online sentiment — into a single AI Score from 0 to 100 and a plain-English Buy, Hold or Sell read. Unlike a traditional analyst rating that updates a few times a year, the AI Score refreshes as new data arrives, so it tracks Tempest Therapeutics’s momentum in near-real time.
Tempest Therapeutics (TPST) has an AltIndex AI Score of 46/100, currently a Hold signal. The AI Score distills Tempest Therapeutics's fundamentals, price technicals and 25+ alternative data signals into a single 0–100 rating, so a rising score reflects strengthening data across the board and a falling score the opposite.
Tempest Therapeutics’s Full AI Analysis
Keep reading AltIndex’s full AI analysis of Tempest Therapeutics — the fundamental, technical and alternative-data breakdown and the recommendation.
Sign up to read the full analysisWhat’s Driving TPST’s AI Score?
Fundamentals
Revenue for the last quarter was $0. This is equal to the revenue of the quarter before it, showing stability. However, compared to the same quarter last year, there is a decrease of 100.00%, which may be a cause for concern. Net income for the last quarter was $-4M. This represents a decrease of 14.53% compared to the quarter before it, indicating a need for concern. Compared to the same quarter last year, there is an increase of -70.89%, suggesting positive year-over-year growth. Ebitda for the last quarter was $-4M. This represents a decrease of 14.83% compared to the quarter before it, indicating a need for concern. Compared to the same quarter last year, there is an increase of -70.73%, suggesting positive year-over-year growth.
See Tempest Therapeutics’s earnings and insider transactions.
Technicals
Today's stock price is $0.95. This represents a decrease of 24.00% compared to a month ago, which may be concerning in the short-term. However, compared to a year ago, there is a decrease of 84.92%, which could be a cause for long-term concern. The trend is bearish. The current SMA10 is $0.98, which is lower than the previous SMA10 of $0.99. This suggests a potential downward trend in price movement. The RSI is 66.4, indicating a neutral condition.
See the full technical analysis and price prediction.
Alternative data
Tempest Therapeutics has an estimate of 2,000 visitors to their webpage. The number of visitors is down by -33% in the last couple of months, a worrisome trend as this can indicate a loss in customers.
Explore Tempest Therapeutics’s job postings, web traffic and app downloads.
Sentiment & social
However, the sentiment is down by -6% in the last couple of weeks, a worrisome trend. Tempest Therapeutics has 390 followers on their Twitter page, with no meaningful increase or decrese in the last couple of months.
Track Tempest Therapeutics’s market sentiment.
Frequently Asked Questions: Tempest Therapeutics AI Stock Analysis
Tempest Therapeutics's AltIndex AI Score is 46/100, currently a Hold signal. The AI Score blends fundamentals, technicals and 25+ alternative data signals into a single rating from 0 to 100.
AltIndex's AI Score model rates Tempest Therapeutics a Hold (46/100). This is a data-driven signal, not investment advice — review the breakdown above and combine it with your own research.
The AI Score is generated from fundamental data (earnings, valuation), technical indicators (price trend and momentum), and alternative data signals such as hiring, web traffic, app downloads and sentiment. AltIndex weighs these into a single 0-100 score; the exact weighting is proprietary.
AltIndex generates a complete written AI analysis of Tempest Therapeutics — company overview, fundamentals, technicals and alternative data, with a recommendation. See the TPST AI Score or sign up to read the full thesis.
